arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Arcturus Therapeutics Holdings Inc.

ARCT Health Care Biotechnology: Pharmaceutical Preparations
$9.84
▼ -11.1% Today
as of Oct 23, 16:45 ET
Last 30 days -35.64% Sep 14 → Oct 23
$9.27 $11.33 $13.39 $15.44 $17.50 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$10.59
High
$10.69
Low
$9.75
Volume
$474,929
Avg Vol
$692,322
Mkt Cap
$375M
P/E (TTM)
—
Beta
—
52w High
$17.96
52w Low
$5.50
Div Yield
—
Shares Out
$28M

Recent Press Releases & News last 60 days · 6 items

Sep 25 · 03:02 MarketBeat
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform
Sep 24 · 10:35 MT Newswires
Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8
Sep 23 · 20:01 PR Business Wire
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
▸ Show all 6 press releases & news Free account →

ARCT earnings at a glance

The options market is pricing a move of about ±9.1% after the report, a range of roughly $8.94 to $10.74 from today's $9.84. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±4.0% on average; after the most recent report on May 7, 2026 it moved -2.5%. That means options currently expect more movement than ARCT has typically delivered. ARCT beat the consensus EPS estimate in 4 of its last 4 reported quarters. Implied volatility is currently 77%. The share price of $9.84 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$5.50
$18
35% of range
Avg surprise (last 4)
+53.5%
Avg reaction (last 2)
+1.5%
50% positive
Latest IV / EM
77%
EM ±9.1% · $13 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.98$-1.02$-0.05$0.91$1.87 Actual $1.87Actual $-1.98Actual $-0.61Actual $-1.00Actual $-0.64Actual $-0.26Actual $-0.52Est $-1.58Actual $-0.34Est $-1.11Actual $-0.49Est $-1.25Actual $-0.95Est $-1.14Actual $-0.84 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-27M$-9M$8M$26M$44M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.84 — — — — financials
Thu May 7, 2026Mar/2026 $-0.95 $-1.14 +16.7% -82.7% -2.5% earnings
Mon Nov 10, 2025Sep/2025 $-0.49 $-1.25 +60.8% — — earnings
Mon Aug 11, 2025Jun/2025 $-0.34 $-1.11 +69.4% — — earnings
Mon May 12, 2025Mar/2025 $-0.52 $-1.58 +67.1% — +5.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.26 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.64 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.00 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.61 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.98 — — — — financials
Fri Mar 31, 2023Mar 2023 $1.87 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$3M$2M—$17M$28M$29M—$42M
Cost of revenue————————
Gross profit————————
Operating income$-26M$-29M—$-17M$-12M$-17M—$-11M
Net income$-24M$-27M—$-13M$-9M$-14M—$-7M
EPS (diluted)$-0.84$-0.95—$-0.49$-0.34$-0.52—$-0.26

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$191M$211M$231M$180M$196M$217M$237M$237M
Inventory————————
Total current assets$197M$217M$241M$249M$275M$279M$306M$331M
Total assets$224M$245M$271M$282M$309M$332M$344M$371M
Long-term debt—————$15M——
Total liabilities$53M$54M$57M$58M$78M$98M$103M$109M
Total equity$172M$191M$214M$225M$231M$234M$241M$262M

Implied volatility — last 90 days

21%165%308%452%596% Jun 07 — IV 114% · EM ±15.8%Jun 08 — IV 117% · EM ±15.4%Jun 09 — IV 153% · EM ±19.2%Jun 10 — IV 157% · EM ±18.6%Jun 11 — IV 39% · EM ±4.3%Jun 12 — IV 168% · EM ±17.2%Jun 15 — IV 247% · EM ±17.9%Jun 16 — IV 59% · EM ±3.5%Jun 17 — IV 390% · EM ±16.3%Jun 19 — IV 75% · EM ±16.6%Jun 22 — IV 79% · EM ±16.6%Jun 23 — IV 85% · EM ±17.3%Jun 24 — IV 96% · EM ±19.3%Jun 25 — IV 86% · EM ±16.9%Jun 26 — IV 95% · EM ±18.2%Jun 29 — IV 81% · EM ±14.3%Jun 30 — IV 93% · EM ±16.0%Jul 01 — IV 91% · EM ±15.2%Jul 02 — IV 83% · EM ±13.4%Jul 03 — IV 86% · EM ±13.4%Jul 06 — IV 110% · EM ±15.3%Jul 07 — IV 102% · EM ±13.5%Jul 08 — IV 107% · EM ±13.4%Jul 09 — IV 100% · EM ±11.8%Jul 10 — IV 156% · EM ±17.2%Jul 13 — IV 192% · EM ±16.0%Jul 14 — IV 456% · EM ±33.0%Jul 15 — IV 596% · EM ±35.2%Jul 20 — IV 32% · EM ±7.5%Jul 21 — IV 22% · EM ±5.0%Jul 22 — IV 29% · EM ±6.7%Jul 23 — IV 166% · EM ±37.4%Jul 24 — IV 168% · EM ±37.1%Jul 27 — IV 96% · EM ±20.0%Jul 28 — IV 121% · EM ±24.8%Jul 29 — IV 110% · EM ±22.0%Jul 30 — IV 160% · EM ±31.2%Jul 31 — IV 236% · EM ±45.1%Aug 03 — IV 492% · EM ±87.1%Aug 04 — IV 229% · EM ±39.4%Aug 05 — IV 115% · EM ±19.2%Aug 07 — IV 71% · EM ±11.1%Aug 10 — IV 136% · EM ±18.8%Aug 13 — IV 113% · EM ±13.4%Aug 14 — IV 74% · EM ±8.2%Aug 17 — IV 213% · EM ±17.8%Aug 18 — IV 278% · EM ±20.1%Aug 19 — IV 191% · EM ±11.3%Aug 20 — IV 430% · EM ±18.0%Aug 24 — IV 114% · EM ±23.9%Aug 25 — IV 96% · EM ±19.7%Aug 26 — IV 107% · EM ±21.5%Aug 27 — IV 103% · EM ±20.1%Aug 28 — IV 97% · EM ±18.6%Aug 31 — IV 90% · EM ±16.0%Sep 01 — IV 106% · EM ±18.2%Sep 02 — IV 116% · EM ±19.4%Sep 03 — IV 97% · EM ±15.7%Sep 04 — IV 108% · EM ±16.9%Sep 07 — IV 122% · EM ±16.9%Sep 08 — IV 113% · EM ±14.9%Sep 09 — IV 106% · EM ±13.2%Sep 10 — IV 133% · EM ±15.7%Sep 11 — IV 111% · EM ±12.2%Sep 14 — IV 145% · EM ±12.1%Sep 15 — IV 188% · EM ±13.6%Sep 16 — IV 138% · EM ±8.2%Sep 17 — IV 110% · EM ±4.6%Sep 21 — IV 93% · EM ±19.4%Sep 22 — IV 104% · EM ±21.2%Sep 23 — IV 108% · EM ±21.6%Sep 24 — IV 90% · EM ±17.7%Sep 25 — IV 89% · EM ±17.0%Sep 28 — IV 71% · EM ±12.6%Sep 29 — IV 88% · EM ±15.1%Sep 30 — IV 73% · EM ±12.2%Oct 01 — IV 85% · EM ±13.8%Oct 02 — IV 65% · EM ±10.2%Oct 06 — IV 95% · EM ±12.5%Oct 07 — IV 73% · EM ±9.2%Oct 08 — IV 77% · EM ±9.1%

Sector peers

EBS
Emergent BioSolutions Inc.
$363M $6.23+0.5%
RLMD
Relmada Therapeutics, Inc.
$390M $3.27+1.9%
TTRX
Turn Therapeutics Inc.
$396M $10.28+1.3%
BNTC
Benitec Biopharma Inc.
$334M $8.65+1.8%
PRLD
Prelude Therapeutics Incorporated
$302M $3.63-0.6%
DMAC
DiaMedica Therapeutics Inc.
$450M $8.72+0.3%

ARCT earnings FAQ

What is ARCT's expected move for earnings?

Options currently price a move of about ±9.1%, or $0.90 per share either way from $9.84.

How does ARCT stock usually react to earnings?

Across the last 2 reports the average next-day move was ±4.0%, up 1 times and down 1 times.

What is ARCT's implied volatility?

ARCT's at-the-money implied volatility is about 77% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in